OTCMKTS:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis $1.62 -0.05 (-2.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.53▼$1.6950-Day Range$1.16▼$2.2252-Week Range$1.03▼$3.67Volume46,249 shsAverage Volume1.17 million shsMarket Capitalization$10.97 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC Filings Get BioRestorative Therapies alerts: Email Address BioRestorative Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside825.9% Upside$15.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.52) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioRestorative Therapies has received no research coverage in the past 90 days.Read more about BioRestorative Therapies' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BRTX. Previous Next 0.0 Dividend Strength Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRTX. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioRestorative Therapies' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($3.52) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About BioRestorative Therapies Stock (OTCMKTS:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesMay 18, 2024 | markets.businessinsider.comStrong Buy Rating for BioRestorative Therapies Amidst Strategic Partnerships and Innovative Clinical ProgressApril 19, 2024 | markets.businessinsider.comOptimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic AdvancesJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.April 17, 2024 | msn.comBioRestorative Therapies (BRTX) Price Target Decreased by 16.00% to 10.71April 14, 2024 | finance.yahoo.com10 Micro-Cap Healthcare Stocks Insiders Are BuyingFebruary 16, 2024 | investing.comBioRestorative Therapies Inc (BRTX)February 14, 2024 | finanznachrichten.deBioRestorative Therapies, Inc.: BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society 2024 Annual MeetingFebruary 6, 2024 | msn.comPRSO, AKRO and MIRA among pre-market losersJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.December 20, 2023 | forbes.comGut Health Could Play A Role In How Blood Cancer Patients Respond To New TherapiesDecember 12, 2023 | marketwatch.comBioRestorative Therapies Shares Rise 14% on Allowance for Patent ApplicationDecember 12, 2023 | finance.yahoo.comBioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity ProgramNovember 9, 2023 | cnet.comBest Light Therapy Lamps for 2023October 9, 2023 | finance.yahoo.comBioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York CitySeptember 18, 2023 | seekingalpha.comBioRestorative Therapies' 10% shareholder Broadrick Dale increases holdingSeptember 18, 2023 | finance.yahoo.comRoth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”September 12, 2023 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 12, 2023 | stockhouse.comBioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSee More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/11/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone(631) 760-8100FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+825.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,500,000.00 Net Margins-13,728.83% Pretax Margin-13,728.83% Return on Equity-120.47% Return on Assets-114.48% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$149,500.00 Price / Sales73.36 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book0.61Miscellaneous Outstanding Shares6,770,000Free Float3,660,000Market Cap$10.97 million OptionableNot Optionable Beta63.43 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 53)Chairman of the Board, President & CEO Comp: $954.17kMr. Robert Eugene Kristal (Age 56)Chief Financial Officer Comp: $368.12kMr. Francisco J. Silva (Age 49)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $891.67kMr. Robert Paccasassi (Age 55)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsLianBioNASDAQ:LIANiBioNYSEMKT:IBIOBiomXNYSEMKT:PHGEPHAXIAM TherapeuticsNASDAQ:PHXMNovaBay PharmaceuticalsNYSEAMERICAN:NBYView All CompetitorsInsidersDale BroadrickBought 1,000 shares on 7/27/2023Total: $2,800.00 ($2.80/share)View All Insider Transactions BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed this year? BioRestorative Therapies' stock was trading at $1.7399 at the start of the year. Since then, BRTX stock has decreased by 6.9% and is now trading at $1.62. View the best growth stocks for 2024 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (OTCMKTS:BRTX) posted its earnings results on Tuesday, June, 11th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.02. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%. When did BioRestorative Therapies' stock split? BioRestorative Therapies's stock reverse split on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioRestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT). This page (OTCMKTS:BRTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioRestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.